Related Experiment Video
Updated: Jun 26, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Emerging drug profile: JAK inhibitors
Alexander Coltoff1, Andrew Kuykendall2
1Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Leukemia & Lymphoma
|May 13, 2024
Summary
Janus kinase (JAK) inhibitors help myelofibrosis patients, but resistance limits effectiveness. Combining JAK inhibitors with other therapies shows promise for better and longer responses in treating this bone marrow disorder.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Dysregulated Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling is a key driver in myelofibrosis pathogenesis.
- JAK inhibitors are a cornerstone of first-line therapy, offering benefits in splenomegaly, symptoms, and cytopenias for myelofibrosis patients.
Purpose of the Study:
- To review the role of JAK/STAT signaling in myelofibrosis.
- To explore potential synergistic therapeutic targets and recent advancements in combination strategies involving JAK inhibitors for myelofibrosis treatment.
Main Methods:
- Review of current literature on JAK/STAT signaling in myelofibrosis.
- Analysis of recent phase III clinical trial data for novel combination therapies.
- Discussion of biological rationale for targeting accessory pathways in conjunction with JAK inhibition.
Main Results:
- Single-agent JAK inhibition provides clinical benefits but is often limited by variable or transient responses due to resistance mechanisms.
- Emerging combination strategies involving novel agents added to JAK inhibitors have met primary endpoints in recent phase III trials.
- Ongoing late-stage studies are investigating further advancements in combination therapies for myelofibrosis.
Conclusions:
- Overcoming JAK inhibitor resistance through combination therapy is crucial for improving patient outcomes in myelofibrosis.
- Targeting cooperating signaling pathways synergistically with JAK inhibitors offers a promising strategy to enhance response rates and durability.
- Future research and clinical trials will continue to refine combination approaches for myelofibrosis management.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131